Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug, Venclexta (Roche/AbbVie’s venetoclax). Launch Tracking Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.

Questions answered:

  • What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
  • What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
  • To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
  • What promotional messages are being employed by Roche/AbbVie?

Scope:

Market covered: United States.

Primary research: 75 hematologist-oncologists; qualitative interviews with 10 respondents.

Indication coverage: Relapsed/refractory CLL.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Emerging Therapies - Venclexta Launch Tracking (US) Wave 2
    • Key Findings
      • Benchmarking Venclexta Launch Success vs. the Competition
        • Venclexta Experiences A Low Level of Use Among Physicians Compared with Other Benchmarking Agents
      • Prescriber and Nonprescriber Profiles
        • Who Is the Venclexta Prescriber?
        • Differences Between Venclexta Prescriber and Nonprescriber Profiles
      • Venclexta Awareness and Perceptions
        • Unaided and Aided Awareness of Venclexta
          • Unaided Awareness of Drugs for Treatment of CLL
          • Awareness of Venclexta
          • Physician Perception of Venclexta's Approved Indications
          • Physician Perception of Venclexta's Administration
          • Awareness of Venclexta's Price
          • Perceived Price of Venclexta
          • Physician Quotes on the Perceived Advantages and Disadvantages of Venclexta
        • Familiarity with Venclexta
          • Mean Level of Familiarity with Venclexta
        • Sources of Familiarity with Venclexta
          • Venclexta Sources of Familiarity
          • Other Sources of Familiarity with Venclexta
        • Initial Reaction to and Interest in Venclexta
          • Venclexta Product Profile
          • Physicians Indicate a Moderate to High Level of Interest in Venclexta
          • Initial Reaction to Venclexta
          • Interest in Venclexta
          • Physician Quotes on Initial Reaction to and Interest in Venclexta
        • Impressions of Venclexta
          • Awareness of Venclexta Profile
          • Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
          • Other Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
          • Uniqueness of Venclexta
          • Perceived Advantages of Venclexta
          • Perceived Disadvantages of Venclexta
          • Value of Venclexta Characteristics
          • Mean Value of Venclexta Characteristics
          • Risk/Benefit Perception of Venclexta
          • Physician Quotes on Impressions of Venclexta
        • Prescriber and Nonprescriber Profiles
        • Venclexta Trial and Use
          • Willingness to Prescribe Venclexta
            • Physician Willingness to Prescribe Venclexta to R/R CLL Patients with Del(17p)
            • Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
            • Mean Value of Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
            • Impact of Venclexta's Accelerated Approval Based on ORR Data of Physician Likelihood to Prescribe
            • Physician Quotes on Willingness to Prescribe Venclexta
          • Number of Patients Currently Receiving Venclexta
            • Venclexta Prescription Rate
            • Patient Share in the Second-Line CLL Del(17p) Setting Now and in Five Months' Time
            • Rituxan-Based Regimens Used in Second-Line Del(17p) Setting Now and in Five Months' Time
            • Patient Share in the Third-Line CLL Del(17p) Setting Now and in Five Months' Time
            • Rituxan-Based Regimens Used in Third-Line Del(17p) Setting Now and in Five Months' Time
            • Other Regimens Used in Third-Line Del(17p) Setting Now and in Five Months' Time
            • Venclexta Discontinuation Rate Among Prescribers
            • Reasons for Discontinuing Venclexta Treatment
            • Treatment Selection Following Venclexta Discontinuation
            • Rituxan-Based Regimens Used Following Venclexta Discontinuation
            • Other Treatments Used Following Venclexta Discontinuation
            • Venclexta Prescribing Practices
            • Treatment Prior to Switching to Venclexta
            • Reasons for Prescribing Venclexta
            • Primary Obstacles to Prescribing Venclexta to More R/R CLL Patients with Del(17p)
            • Patient Inquiries Regarding Venclexta in Past Month
            • Mean Number of Patient Inquiries Regarding Venclexta in Past Month
            • Hematologist-Oncologists' Action Based on Specific Patient Inquiries
            • Physician Quotes on Current Use of Venclexta
          • Reasons for Not Yet Prescribing Venclexta
            • Key Reasons for Not Yet Prescribing Venclexta
            • Other Reasons for Not Yet Prescribing Venclexta
            • Physician Quotes on Reasons for Not Prescribing Venclexta
          • Anticipated Venclexta Use
            • Anticipated Venclexta Use Among Nonprescribers
            • Percentage of Second-Line and Third-Line CLL Patients Eligible for Venclexta
            • Potential Displacement of Existing Treatments by Venclexta
            • Rituxan-Based Therapies Likely to Be Replaced by Venclexta
            • Physician Quotes on Anticipated Venclexta Use
          • Venclexta Performance on Key Attributes
            • Overall Level of Satisfaction with Venclexta for Treatment of R/R CLL with Del(17p)
            • Level of Satisfaction with Venclexta on Key Metrics
            • Mean Levels of Satisfaction with Venclexta on Key Attributes
            • Physician Rating of Venclexta on Key Attributes
            • Performance of Venclexta on Key Attributes
            • Physician Quotes on Venclexta Performance on Key Attributes
        • Effectiveness of Face-to-Face Detailing for Venclexta
          • Venclexta Sales Representative Frequency and Reach
            • Last Time of Contact with a Venclexta Representative
            • Physician Quotes on Venclexta Sales Representative Visit Frequency and Reach
          • Satisfaction with Venclexta Sales Representative
            • Sales Representative Performance on Key Attributes
            • Physician Quotes on Satisfaction with Venclexta Sales Representatives
          • Venclexta Message Recall
            • Topics Discussed by Sales Representatives
            • Positioning of Venclexta Against Other Products
        • Methodology
          • Primary Market Research Methodology
          • Distribution of Hematologist-Oncologists by State
          • Distribution of Hematologist-Oncologists by Region
          • Practice Type
          • Percentage of Professional Time Devoted to Direct Patient Care
          • Years in Clinical Practice
          • Patient Load by Disease Classification
          • Mean Values of Patient Load by Disease Classification
          • CLL Patient Load by Del(17p) Status
          • Primary Practice Location
          • Venclexta Sales Representative Performance Mean Rating Across Key Attributes
        • Appendix
          • Abbreviations

        Author(s): Dana Gheorghe

        Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.


        Related Reports

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

        The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

        View Details

        Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020

        The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-y...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Incyte Proprietary Content

        In this project, commissioned by Incyte in February, 2021, we have packaged our published estimates on the epidemiology of NHL & CLL across all the countries in Europe for which we have coverag...

        View Details

        Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

        In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

        View Details